摘要:
Compounds which are alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Q is a monocyclic or bicyclic optionally-substituted heterocyclic ring as defined herein; Z is —C(═O)— or —S(═O)2—; R and R′ are lower alkyl; R5 is halogen, cyano, hydroxy, —R6, or —OR6; and R6 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclo, or substituted heterocyclo; and pharmaceutically-acceptable salts, hydrates, prodrugs, and isomers thereof.
摘要翻译:作为α-1A / B肾上腺素受体拮抗剂并由式I表示的化合物:其中Q是如本文所定义的单环或双环任选取代的杂环; Z是-C(-O) - 或-S(-O)2 - 。 R和R'是低级烷基; R 5是卤素,氰基,羟基,-R 6或-OR 6; R 6是烷基,取代的烷基,芳基,取代的芳基,杂芳基,取代的杂芳基,环烷基,取代的环烷基,杂环或取代的杂环; 及其药学上可接受的盐,水合物,前体药物和异构体。
摘要:
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.
摘要翻译:本发明涉及通常为IP受体拮抗剂并由式I表示的化合物:其中:R 1,R 2和R 3, 各自独立地为芳基或杂芳基; R 4是-COOH或四唑基; A,B,m,n和r如说明书中所定义; 或各异构体,异构体的外消旋或非外消旋混合物,或其药学上可接受的盐或溶剂合物。 本发明还涉及含有这些化合物的药物组合物,其用作治疗剂的方法及其制备方法。
摘要:
This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.
摘要:
Compounds of the formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein m, R1, R2, R3, R4, R5 and R6 are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula (I).
摘要:
A method and apparatus for purifying industrial waste fluids by an aerobic biological treatment is provided herein, which is capable of concurrently purifying waste gases emanating from such waste liquids. The improvement relates to the elimination or reduction of odors and volatile organic substances by enclosing all tanks and basins from the influent of the waste water treatment plant up to the aeration treatment zone for the liquid waste water and venting these gases to an aerobic digester and/or an aeration basin to biologically decompose or degrade the VOS in the waste gas by action of the microorganisms in the aeration basin or aerobic digester.
摘要:
A method and apparatus for purifying industrial waste fluids by an aerobic biological treatment is provided herein, which is capable of concurrently purifying waste gases emanating from such waste liquids. The improvement relates to the elimination or reduction of odors and volatile organic substances by enclosing all tanks and basins from the influent of the waste water treatment plant up to the aeration treatment zone for the liquid waste water and venting these gases to an aerobic digester and/or an aeration basin to biologically decompose or degrade the VOS in the waste gas by action of the microorganisms in the aeration basin or aerobic digester.